BTRS (NASDAQ: BTRS – Get Rating) and Decision Diagnostics (OTCMKTS: DECN – Get Rating) are both small cap business services companies, but which is the best investment? We’ll compare the two companies based on earnings strength, dividends, valuation, analyst recommendations, institutional ownership, risk and profitability.
This is a breakdown of the current recommendations for BTRS and Decision Diagnostics, as reported by MarketBeat.
|Sales Ratings||Hold odds||Buy reviews||Strong buy odds||Rating|
|Decision-making diagnosis||0||0||0||0||N / A|
BTRS currently has a consensus price target of $11.67, suggesting a potential upside of 63.63%. Given the higher possible upside of BTRS, research analysts clearly believe that BTRS is more favorable than Decision Diagnostics.
This table compares the net margins, return on equity and return on assets of BTRS and Decision Diagnostics.
|Net margins||Return on equity||return on assets|
|Decision-making diagnosis||N / A||N / A||N / A|
Risk and Volatility
BTRS has a beta of 0.44, indicating that its stock price is 56% less volatile than the S&P 500. In comparison, Decision Diagnostics has a beta of -2.16, indicating that its stock price is 316% less volatile than the S&P 500.
Insider and Institutional Ownership
73.7% of BTRS shares are held by institutional investors. By comparison, 0.0% of Decision Diagnostics shares are held by institutional investors. Strong institutional ownership indicates that hedge funds, large fund managers, and endowments believe a stock will outperform the market over the long term.
Benefits and evaluation
This table compares the revenue, earnings per share and valuation of BTRS and Decision Diagnostics.
|Gross revenue||Price/sales ratio||Net revenue||Earnings per share||Price/earnings ratio|
|BTRS||$166.40 million||6.80||-$61.20 million||($0.40)||-17.82|
|Decision-making diagnosis||N / A||N / A||N / A||N / A||N / A|
Decision Diagnostics has lower earnings, but higher earnings than BTRS.
BTRS beats Decision Diagnostics on 5 of the 8 factors compared between the two stocks.
About BTRS (Get an evaluation)
BTRS Holdings Inc. provides cloud-based software and integrated payment processing solutions that automate business-to-business (B2B) commerce worldwide. The Company operates in two segments, Printing, and Software and Payments. The company offers solutions that cover credit decision and monitoring, online ordering, invoicing, cash application and collections. Its products include Credit Application, a B2B credit application module, which provides a digital process that provides real-time credit information to streamline prospect assessment and new customer onboarding during sales activity. initial ; Credit Management, a credit management module, which provides continuous risk assessment for its customers’ customers; ordering/e-commerce module that provides B2B wholesalers with e-commerce capabilities; and an invoicing module, which allows its customers to optimize the delivery of invoices on different distribution channels. The Company’s products also include integrated B2B payments, integrated payment capabilities that enable customers to facilitate payments at every possible touchpoint across the solution set; the treasury application module, which enables the reconciliation of income through the reconciliation of line items in the accounting and ERP systems; a collections module that allows customers to move from a reactive model centered on collection to a strategic operation centered on the customer touchpoint, avoiding late payments and promoting positive customer experiences; and the Enterprise Payments Network, which enables accepting electronic payments by connecting vendors and their underlying systems, AP portals, payment card issuers, banks, and payment processors. It serves clients in various verticals, including technology, healthcare, industrials, wholesale distribution, consumer packaged goods and others. The company was incorporated in 2001 and is based in Lawrenceville, New Jersey.
About decision diagnostics (Get an evaluation)
Decision Diagnostics Corp. develops electronic medical record (EMR) technologies based on smartphones. The company offers prescription and non-prescription diagnostics; home screening products for the chronically ill; implementation services to direct patients’ diabetes programs; and e-health technology and product development services focused on cellphones. It manufactures and distributes GenUltimate! glucose test strips, a class II medical device for home use for measuring glucose; PetOf course! glucose test strip for glucose testing of dogs and cats designed to work with Zoetis AlphaTrak and AlphaTrak II glucometers, an older meter; GenUltimate! 4Pets Glucose system, an exclusive glucose measurement system, including GenUltimate! 4Pets Test Strip and Advantage Reader, for testing dogs, cats and horses; and GenUltimate! Of course and GenUltimate! Accurate test strips. In addition, it engages in the acquisition and ownership of intellectual property, including patents and trademarks and specialized manufacturing equipment. Additionally, the company also provides [email protected], an inpatient/outpatient management suite; Practice Probe, a data mining utility used to extract information from the physician’s practice management system; and ResidenceWare, a residential management system that facilitates the relay of information from commercial and residential property management companies to tenant occupiers using software systems and networking applications. Its EMR technologies are used by physicians at the point of care. The company was previously known as InstaCare Corp. and changed its name to Decision Diagnostics Corp. in November 2011. Decision Diagnostics Corp. was founded in 2000 and is based in Westlake Village, California.
Get news and reviews for BTRS Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for BTRS and related companies with MarketBeat.com’s free daily email newsletter.